

# Cerebral Palsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/C7E62AF98124EN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: C7E62AF98124EN

## Abstracts

The 7 major cerebral palsy markets reached a value of US\$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 2.5 Billion by 2034, exhibiting a growth rate (CAGR) of 2.53% during 2024-2034.

The cerebral palsy market has been comprehensively analyzed in IMARC's new report titled "Cerebral Palsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cerebral palsy refers to a group of neurological conditions that affect body's movement and posture. The symptoms of the ailment vary widely from person to person and may include poor muscle control as well as coordination, abnormal muscle tone, spasticity (stiffness of the muscles), ataxia (incoordination and lack of balance), tremors or involuntary movements, difficulty with speech and communication, vision or hearing problems, cognitive impairments, etc. The severity of the indications can range from mild to severe and may affect different parts of the body, such as the arms, legs, face, etc. Diagnosing the ailment typically involves a comprehensive investigation by a team of healthcare professionals, including a neurologist, developmental pediatrician, physical therapist, etc. The evaluation consists of a review of medical history and symptoms, a physical examination, and various diagnostic tests, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, genetic testing, electromyography (EMG), movement analysis, etc. Various standardized assessments, including the Gross Motor Function Classification System (GMFCS) and the Manual Ability Classification System (MACS), are also used to evaluate motor function and level of disability in children with cerebral palsy.

The increasing cases of prenatal, perinatal, and postnatal brain damage are primarily driving the cerebral palsy market. Additionally, the rising prevalence of maternal health

factors, such as infections, high blood pressure, gestational diabetes, etc., which can increase the risk of cerebral palsy in the child, is also creating a positive outlook for the market. Moreover, the escalating utilization of several medications, including baclofen, botulinum toxin injections, anticonvulsants, etc., to treat specific symptoms, such as muscle spasticity and seizures, is further augmenting the market growth. Besides this, the widespread adoption of selective dorsal rhizotomy, in which the sensory nerve roots in the spinal cord are selectively cut to reduce spasticity and improve mobility, as a treatment option is also propelling the market growth. Furthermore, various key players are making extensive investments in developing novel diagnostic devices that can aid in identifying anatomical abnormalities in the brain associated with cerebral palsy. This, in turn, is acting as another significant growth-inducing factor. Additionally, the introduction of assistive technology, such as mobility aids, communication devices, adaptive equipment, etc., that help patients to improve their quality of life is expected to drive the cerebral palsy market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the cerebral palsy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cerebral palsy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cerebral palsy market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the cerebral palsy market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the cerebral palsy market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current cerebral palsy marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

## Market Insights

How has the cerebral palsy market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the cerebral palsy market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the cerebral palsy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of cerebral palsy across the seven major markets?

What is the number of prevalent cases (2018-2034) of cerebral palsy by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of cerebral palsy by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of cerebral palsy by type across the seven major markets?

How many patients are diagnosed (2018-2034) with cerebral palsy across the seven major markets?

What is the size of the cerebral palsy patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of cerebral palsy?

What will be the growth rate of patients across the seven major markets?

## Cerebral Palsy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for cerebral palsy drugs across the seven

major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cerebral palsy market?

What are the key regulatory events related to the cerebral palsy market?

What is the structure of clinical trial landscape by status related to the cerebral palsy market?

What is the structure of clinical trial landscape by phase related to the cerebral palsy market?

What is the structure of clinical trial landscape by route of administration related to the cerebral palsy market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 CEREBRAL PALSY - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 CEREBRAL PALSY - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 CEREBRAL PALSY - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Epidemiology by Type (?2018-2034?)
  - 7.2.6 Diagnosed Cases (?2018-2034?)
  - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Epidemiology by Type (?2018-2034?)
  - 7.3.6 Diagnosed Cases (?2018-2034?)
  - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Epidemiology by Type (?2018-2034?)
  - 7.4.6 Diagnosed Cases (?2018-2034?)
  - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Epidemiology by Type (?2018-2034?)
  - 7.5.6 Diagnosed Cases (?2018-2034?)
  - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Epidemiology by Type (?2018-2034?)
  - 7.6.6 Diagnosed Cases (?2018-2034?)



- 7.6.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)
  - 7.7.4 Epidemiology by Gender (?2018-2034?)
  - 7.7.5 Epidemiology by Type (?2018-2034?)
  - 7.7.6 Diagnosed Cases (?2018-2034?)
  - 7.7.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Epidemiology by Type (?2018-2034?)
  - 7.8.6 Diagnosed Cases (?2018-2034?)
  - 7.8.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Epidemiology by Type (?2018-2034?)
  - 7.9.6 Diagnosed Cases (?2018-2034?)
  - 7.9.7 Patient Pool/Treated Cases (?2018-2034?)

## **8 CEREBRAL PALSY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 CEREBRAL PALSY - UNMET NEEDS**

## **10 CEREBRAL PALSY - KEY ENDPOINTS OF TREATMENT**

## **11 CEREBRAL PALSY - MARKETED PRODUCTS**

- 11.1 List of Cerebral Palsy Marketed Drugs Across the Top 7 Markets



- 11.1.1 Drug Name – Company Name
  - 11.1.1.1 Drug Overview
  - 11.1.1.2 Mechanism of Action
  - 11.1.1.3 Regulatory Status
  - 11.1.1.4 Clinical Trial Results
  - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

## **12 CEREBRAL PALSY - PIPELINE DRUGS**

### 12.1 List of Cerebral Palsy Pipeline Drugs Across the Top 7 Markets

- 12.1.1 UDI-001 - Rohto Pharmaceutical
  - 12.1.1.1 Drug Overview
  - 12.1.1.2 Mechanism of Action
  - 12.1.1.3 Clinical Trial Results
  - 12.1.1.4 Safety and Efficacy
  - 12.1.1.5 Regulatory Status
- 12.1.2 Botulinum toxin type A - Hugel
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 Valbenazine - Neurocrine Biosciences
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 Epoetin alfa biosimilar - LG Chem
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status
- 12.1.5 AlloRx- Vitro Biopharma
  - 12.1.5.1 Drug Overview
  - 12.1.5.2 Mechanism of Action
  - 12.1.5.3 Clinical Trial Results

12.1.5.4 Safety and Efficacy

12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

### **13. CEREBRAL PALSY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. CEREBRAL PALSY – CLINICAL TRIAL LANDSCAPE**

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

### **15 CEREBRAL PALSY - MARKET SCENARIO**

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Cerebral Palsy - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Cerebral Palsy - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Cerebral Palsy - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Cerebral Palsy - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Cerebral Palsy - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Cerebral Palsy - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Cerebral Palsy - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

- 15.4.2.2 Market Forecast by Therapies (2024-2034)
- 15.4.3 Cerebral Palsy - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Cerebral Palsy - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Cerebral Palsy - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Cerebral Palsy - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Cerebral Palsy - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Cerebral Palsy - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Cerebral Palsy - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Cerebral Palsy - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Cerebral Palsy - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Cerebral Palsy - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Cerebral Palsy - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Cerebral Palsy - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Cerebral Palsy - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Cerebral Palsy - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Cerebral Palsy - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Cerebral Palsy - Access and Reimbursement Overview

## **16 CEREBRAL PALSY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 CEREBRAL PALSY MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 CEREBRAL PALSY MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Cerebral Palsy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/C7E62AF98124EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C7E62AF98124EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

